Page 1
Instructions for use
Title A small oxazine compound as an anti-tumor agent : A novel pyranoside mimetic that binds to VEGF, HB-EGF, andTNF-α
Author(s) Basappa; Murugan, Sengottuvelan; Kavitha, Chandagirikoppal V.; Purushothaman, Anurag; Nevin, Kottayath G.;Sugahara, Kazuyuki; Rangappa, Kanchugarakoppal S.
Citation Cancer Letters, 297(2), 231-243https://doi.org/10.1016/j.canlet.2010.05.016
Issue Date 2010-11-28
Doc URL http://hdl.handle.net/2115/49204
Type article (author version)
Additional Information There are other files related to this item in HUSCAP. Check the above URL.
File Information Supplementary_material.pdf
Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP
Page 2
Basappa et al., Supplemental Material
Experimental Procedures
Chemistry
Supplemental Scheme 1. General procedure for the synthesis of FMBO, CMBO, and
PMBO. Equimolar solution of aldehydes (R1-CHO) and 1-[2-amino-1-(4-methoxy-
phenyl)-ethyl]-cyclohexanol monoacetate were mixed in 5.0 ml of methanol in the
presence of anhydrous K2CO3 and the reaction mixture was stirred at room temperature
for 10-12 h. After the reaction complete, evaporated the methanol, water was added and
the reaction mass was extracted three times with ethyl acetate. After drying over Na2SO4
and evaporation of the organic solvent in vacuo, purified the compounds using column
chromatography (solvent system: chloroform: methanol (9:1).
OCH3
NH2
OH
OCH3
O
NH
R1
K2CO3/ Methanol / RT
R1-CHO
Acetate Salt Oxazine Derivatives
A. Synthesis of FMBO. FMBO was obtained from an amino alcohol (1g, 3.23 mmol), 4-
fluoro benzaldehyde (0.48g, 3.88mmol) and anhydrous Na2CO3 (1.37g, 12.94 mmol) as
amorphous white solid (0.8g, 80%). Mp 130 0C. IR νmax (KBr): 3212, 2945, 1520, 1240
cm-1. 1H NMR (CDCl3 400 MHz) δ: 7.61 (2H, d, J=5.5, Ar-H), 7.15 (5H, m, J=6, Ar-H),
6.86 (2H, d, J=6.5, Ar-H), 5.31 (1H, d, NH), 3.75 (3H, s, OCH3), 3.50 (1H, d, CH2-CH),
3.32 (3H, s, Ar-CH), 2.41-2.92 (2H, m, CH-CH2), 1.30-1.75 (10H, m, cyclohexyl). Anal.
(C22H26FNO2) C, H, N.
B. Synthesis of CMBO. CMBO was obtained from an amino alcohol (1g, 3.23 mmol), 4-
chloro benzaldehyde (0.54g, 3.88mmol) and anhydrous Na2CO3 (1.37g, 12.94 mmol) as
Page 3
colourless crystalline solid (0.78g, 78%). Mp 80 0C. IR νmax (KBr): 3209, 2933, 1523,
1238, 1008 cm-1. 1H NMR (CDCl3 400 MHz) δ: 7.58 (2H, d, J=14.1, Ar-H), 7.45 (2H, d,
J=15.6, Ar-H), 7.12 (2H, d, J =8.4, Ar-H), 6.88 (2H, d, J=8.7, Ar-H), 5.33 (1H, d, NH),
3.73 (3H, s, OCH3), 3.50 (1H, d, CH), 3.32 (3H, s, Ar-CH), 2.51-2.72 (2H, m, CH-CH2),
1.30-1.75 (10H, m, cyclohexyl). Anal. (C22H26ClNO2) C, H, N.
C. Synthesis of PMBO. PMBO was obtained from an amino alcohol (1g, 3.23 mmol),
pyridin-3-aldehyde (0.41g, 3.88 mmol) and anhydrous Na2CO3 (1.37g, 12.94mmol) as
amorphous white solid (0.78g, 78%). Mp 840C. IR νmax (KBr): 3089, 2868, 1627, 1508,
1232 cm-1. 1H NMR (CDCl3 400 MHz) δ: 8.91 (1H, s, Ar-H), 8.65 (1H, d, J=7, Ar-H),
7.95 (1H, d, J=7.6 Ar-H), 7.42 (1H, t, J=7.6, Ar-H), 7.15 (2H, d, Ar-H), 5.45 (1H, s,
NH), 3.80 (3H, s, OCH3), 3.62 (1H, t, CH-CH2), 3.34 (3H, s, Ar-CH), 2.51-2.90 (m, 1H,
CH-CH2), 0.91-1.85 (10H, m, cyclohexyl). Anal. (C21H26N2O2) C, H, N.
Biology
Hyaluronidase Digestion Assay: FITC-labelled hyaluronic acid (HA) (20 μg) was incubated
with 2 mIU of hyaluronidase (from Streptomyces hyalurolytics) in the presence or absence of
DMBO (100 μM) in a total volume of 50 μl of 20 mM acetate–Na buffer, pH 6.0 at 60°C for
4h. The digests were subjected to gel filtration HPLC on a Superdex 200 (GE Healthcare) at a
flow rate of 0.4 mL/min using 0.2 M NH4HCO3 as the eluent. Eluates were monitored by
measuring fluorescence with excitation and emission wavelengths of 490 and 520 nm,
respectively (1).
Chondroitinase ABC digestion Assay: Chondrotin sulfate (CS)-A (2 μg) from whale
cartilage, was digested with chondroitinase (CSase) ABC (10 mIU) (2) in the presence or
absence of DMBO (100 μM) and labeled with 2-Aminobenzamide (2AB) (3). The excess
Page 4
2AB was removed by extraction with chloroform (4). The 2AB-labeled digest was analyzed
by anion exchange HPLC on a PA-03 silica column (YMC-Pack PA, Kyoto, Japan) with a
linear gradient of NaH2PO4 from 16 to 538 mM over 60 min at a flow rate of 1.0 mL/min at
room temperature. Identification and quantification of the resulting disaccharides were
achieved by comparison with the elution of authentic CS-derived unsaturated disaccharides
(3).
References
1. Li F., Yamada, S., Basappa,. Shetty, A. K., Sugiura, M., Sugahara, K. (2008).
Glycoconj J. 25, 603-610.
2. Saito, H., Yamagata, T., Suzuki, S. (1968). J Biol Chem. 243, 1536–1542.
3. Kinoshita A, Sugahara K. (1999). Anal Biochem. 269, 367–378.
4. Kawashima, H., Atarashi, K., Hirose, M., Hirose, J., Yamada, S., Sugahara, K.,
Miyasaka, M. (2002). J Biol Chem. 277, 12921–12930.
Page 5
Figure legends
Supplemental Fig. 1. The structure of the photo-affinity linker and the dummy thiol linker.
Supplemental Fig. 2. The SPR signal image for VEGF bound with immobilized DMBO and
its location on PGSs. The interaction between DMBO and VEGF (arrows) was quantified
using an SPR analyzer. The IUPAC names of the other small molecules are as follows:
CMBO: 2-(4-Chlorophenyl)-4a,5,6,7,8,8a-hexahydro-4a-(4-methoxyphenyl)-4H-
benzo[e][1,3]oxazine; PMBO: 2-(3-Pyridyl)-4a,5,6,7,8,8a-hexahydro-4a-(4-methoxyphenyl)-
4H-benzo[e][1,3] oxazine; KSB110: (2-Ethoxyphenyl)(4-(6-fluorobenzo[d]isoxazol-3-
yl)piperidin-1-yl) methanone; RS01: 2-Butyl-4-chloro-5-(2,5-diphenylisoxazolidin-3-yl)-1H-
imidazole; KSB76: 1-(2-Bromo-4,5-dimethoxybenzyl)-2-butyl-4-chloro-1H-imidazole-5-
carbaldehyde; KSB75: 2-Butyl-4-chloro-1-((5-methylbenzo[d][1,3]dioxol-6-yl)methyl-1H-
imidazole-5-carbaldehyde; KSB58: 4’-(2-Butyl-4-chloro-5-formyl-imidazol-1-ylmethyl)-
biphenyl-2-carbonitrile; KSB78: 2-Butyl-4-chloro-1-((4,5-dihydro-5-methylisoxazol-4-
yl)methyl)-1H-imidazole-5-carbaldehyde; KSB28: 4-(2,6-Difluorobenzylideneamino)-5-
ethyl-4H-1,2,4-triazole-3-thiol; KSB29: 4-(2,6-Difluorobenzylideneamino)-5-phenyl-4H-
1,2,4-triazole-3-thiol; KSB07: 4-(2,6-Difluorobenzylideneamino)-5-(4-chlorophenyl-4H-
1,2,4-triazole-3-thiol; KSB52: 4-(2,6-Difluorobenzylideneamino)-5-ethyl-4H-1,2,4-triazole-
3-thiol; KSB34: 2-Butyl-1,5,6,7a-tetrahydro-5-methylimidazo[4,5-e][1,3]thiazin-(2-methyl-
3,4-triazolo)-7(3aH)-imine.
Supplemental Fig. 3. The SPR signal image for TNF-α bound with immobilized DMBO and
its location on PGSs. The interaction between DMBO and TNF (arrows) was quantified using
an SPR analyzer. The IUPAC names of the other small molecules are described in the legend
to Supplemental Fig. 2.
Supplemental Fig. 4. The SPR signal for HB-EGF bound with immobilized DMBO and its
location on PGSs. The interaction between DMBO and HB-EGF (arrows) was quantified
using an SPR analyzer. The IUPAC names of the other small molecules are described in the
legend to Supplemental Fig. 2.
Supplemental Fig. 5. Interaction of FGF-2 with DMBO and other oxazine molecules. Bar
graph depicts the maximum SPR signal strength for FGF-2 binding with immobilized oxazine
molecules. Oxazine molecules (10 mM) were immobilized on the PGSs and their interactions
with FGF-2 were detected in solution by SPR imaging.
Page 6
Supplemental Fig. 6. Interaction of midkine with DMBO and other oxazine molecules. Bar
graph depicts the maximum SPR signal strength for midkine binding with immobilized
oxazine molecules. Oxazine molecules (10 mM) were immobilized on the PGSs and their
interactions with midkine were detected in solution by SPR imaging. The location of DMBO
and other oxazine molecules on PGSs is presented.
Supplemental Fig. 7. Interaction of pleotrophin with DMBO and other oxazine molecules.
Bar graph depicts the maximum SPR signal strength for pleotrophin binding with
immobilized oxazine molecules. Oxazine molecules (10 mM) were immobilized on the PGSs
and their interactions with pleotrophin were detected in solution by SPR imaging.
Supplemental Fig. 8. Interaction of BSA with DMBO and other oxazine molecules. Bar
graph depicts the maximum SPR signal strength for BSA binding with immobilized oxazine
molecules. Oxazine molecules (10 mM) were immobilized on the PGSs and their interactions
with BSA were detected in solution by SPR imaging.
Supplemental Fig. 9. Histopathological studies of liver and kidney in normal and DMBO
treated mice. The toxic effects of DMBO ((1.5 mg/kg, the highest dose) were evaluated by
histopathological examination of the liver and kidney section by hematoxylin & eosin (H&
E) staining. Representative photomicrographs of normal and DMBO treated liver (A and B),
and kidney (C and D) respectively. Normal and DMBO treated animals show normal-
appearing hepatocyte parenchyma (A and B), kidney glomerulai and tubules (C and D).
Magnification 20X.
Supplemental Fig. 10. DMBO does not inhibit hyaluronidase enzymatic degradation of
FITC-HA. Chromatogram of FITC-labelled HA alone (20 μg) (top panel), digested by the
hyaluronidase (2 mIU) in the presence (last panel) and absence (middle panel) of DMBO
(100 μM) as inhibitor. The mixture was incubated at 60°C for 4h and the samples solutions
were subjected to gel filtration chromatography on a Superdex 200 column equilibrated with
0.2 M NH4HCO3. Eluates were monitored by measuring fluorescence with excitation and
emission wavelengths of 490 and 520 nm, respectively. The undegraded FITC-HA (top
panel) was eluted near the void volume or the degraded FITC-HA by the enzyme
hyaluronidase in the absence (middle panel) or in the presence of DMBO (bottom panel), had
a longer retention time than the control, undegraded FITC-HA. The results shows that FITC-
HA was specifically degraded, indicating that hyaluronidase is active even in the presence of
DMBO.
Page 7
Supplemental Fig. 11. Anion-exchange HPLC analysis of CSase ABC digests of the CS-A.
The CS-A was digested with CSase ABC in the presence or absence of DMBO (100 μM).
After 2AB-labeling, each digest was analyzed by HPLC on an amine-bound silica PA-03
column using a linear gradient of NaH2PO4 as indicated by the dashed line. The peaks before
10 min were derived from 2AB-derivatizing reagents. Upper panel, CS-A was digested with
CSase ABC with DMBO (100 μM); lower panel, CS-A was digested with CSase ABC
without DMBO. Arrows indicate the elution positions of unsaturated disaccharide standards:
(1) Δ4,5HexUA-GlcNAc; (2) Δ4,5HexUA-GalNAc; (3) Δ4,5HexUA-GalNAc(6S); (4)
Δ4,5HexUA-GalNAc(4S); (5) Δ 4,5HexUA(2S)-GalNAc(6S); (6) Δ4,5HexUA-GalNAc(4S, 6S).
.
Page 8
Basappa et al.,
Suppl. Figure 1
HSC11H22OO
O
HN
OO
NH
O
CF3
NN4
HSC11H22OO
OOH
Photo-affinity thiol linker
Dummy thiol
Page 9
Basappa et al.,
Suppl. Figure 2
KSB46 KSB43 DMBO KSB110 RS01
KSB76 KSB75 KSB58 KSB78 DMSO
KSB46 KSB43 DMBO RS01 KSB110
KSB28 KSB29 KSB07 KSB52 KSB34
Page 10
Basappa et al.,
Suppl. Figure 3
KSB46 KSB43 DMBO KSB110 RS01
KSB76 KSB75 KSB58 KSB78 DMSO
KSB46 KSB43 DMBO RS01 KSB110
KSB28 KSB29 KSB07 KSB52 KSB34
Page 11
Basappa et al.,
Suppl. Figure 4
KSB46 KSB43 DMBO KSB110 RS01
KSB76 KSB75 KSB58 KSB78 DMSO
KSB46 KSB43 DMBO RS01 KSB110
KSB28 KSB29 KSB07 KSB52 KSB34
Page 12
Basappa et al.,
Suppl. Figure 5
Page 13
Basappa et al.,
Suppl. Figure 6
Page 14
Basappa et al.,
Suppl. Figure 7
Page 15
Basappa et al.,
Suppl. Figure 8
Page 16
Basappa et al., Suppl. Figure 9
C D
A B
Page 17
Basappa et al., Suppl. Figure 10
Time (min)
Page 18
Basappa et al., Suppl. Figure 11
1 2 3 5 64
1 2 3 5 64
Page 19
Supplementary Table 1: Inhibition of the proliferation of tumor cells by MBO, FMBO, CMBO or
PMBO.
Anti-proliferative activity (IC50 in μM) Compound R1
LM8 LM8G7 SKOV-3 OVSAHO
1 H NSa NS NS NS
2 4-Fluoro-phenyl 64 ± 0.5 86 ± 0.1 74 ± 0.6 94 ± 0.4
3 4-Chloro-phenyl NS >100 >100 21 ± 2
4 pyridine-3-yl 95 ± 6 NS 65 ± 0.5 NS
aNot significant